PLUS THERAPEUTICS INC (PSTV)
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
$3.10+2.65%
Close 2026-08-27 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-30
Research Workspace
Put PSTV beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Primary pillar under pressure — reduce net loss from -$3.92 per share in 2026 to -$2.4 per share in 2027: Comparison needs review.
View ThesisMiddle-of-the-pack management execution.
View ManagementThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 87% in its worst 12-month stretch.
View RiskPSTV’s claim rests on its ability to recover after severe revenue decline. Its latest quarter’s revenue fell 70% year over year, with an earnings miss. The stock’s price cannot be judged against peers because valuation data is missing. The next-quarter earnings miss probability is 58%, a specific risk to that recovery claim. Its 2026 loss-reduction pillar needs review because the comparison is unverified. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-08-27. PSTV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 4 analysts currently covering PSTV (as of Aug 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare PSTV with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| PSTV Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put PSTV next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-08-27. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.